Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 11/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30812811 | 1.00 | P2RX4 (0.51) | P2RX4SMN1; SMN2ANO1LMNARECQL | |
| SCHEMBL23619951 | 0.95 | ANO1 (0.52) | P2RX4SMN1; SMN2ANO1LMNA | |
| SCHEMBL30812901 | 0.95 | ANO1 (0.52) | P2RX4SMN1; SMN2ANO1LMNA | |
| SCHEMBL30812858 | 0.94 | P2RX4 (0.54) | P2RX4SMN1; SMN2LMNA | |
| SCHEMBL23619838 | 0.94 | P2RX4 (0.54) | P2RX4SMN1; SMN2LMNA | |
| SCHEMBL23619912 | 0.90 | P2RX4 (0.57) | P2RX4 | |
| SCHEMBL30812812 | 0.90 | P2RX4 (0.57) | P2RX4 | |
| SCHEMBL23619872 | 0.88 | P2RX4 (0.44) | P2RX4SMN1; SMN2ANO1 | |
| SCHEMBL30812914 | 0.88 | P2RX4 (0.44) | P2RX4SMN1; SMN2ANO1 | |
| SCHEMBL23619956 | 0.87 | P2RX4 (0.46) | P2RX4SMN1; SMN2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079724-B1 | 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| CN-114901642-B | Fused ring compound and application thereof | 武汉朗来科技发展有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-114901642-A | Fused ring compound and application thereof | 武汉朗来科技发展有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | P2RX4 1/4885SMN1; SMN2 2862/4885ANO1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.